THE PROBLEM OF NEUROENDOCRINE DYSFUNCTIONS IN PATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER (literature review)

Authors

  • Pidkorytov V. S. V. S. Pidkorytov
  • Syerikova O. I. SI «Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine», Kharkiv
  • Serikova O. S. SI «Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine», Kharkiv
  • Baybarak N. A. SI «Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine», Kharkiv
  • Ukrayinskyy S. A. SI «Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine», Kharkiv
  • Skrynnik O. V. SI «Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine», Kharkiv

DOI:

https://doi.org/10.21856/j-PEP.2016.3.11

Keywords:

schizophrenia spectrum disorders, neuroendocrine dysfunctions, atypical antipsychotics

Abstract

Neuroendocrine dysfunctions (NED) are often observed in patients with schizophrenia spectrum disorders and could be a component of the etiopathogenesis of the disease as well as effect associated with use of atypical neuroleptics. The most common NED symptoms and syndromes are described in the literature review: neuroleptic-induced hyperprolactinemia syndrome, the frequency of occurrence 2–100 %, metabolic syndrome — a 49.3 %, increasing in body weight (neuroleptics obesity) — 40–92 %, diabetes mellitus type 2 — 6.2–25.0 %, violation of thyroid metabolism — 20–49 %, a polymorphic syndrome — 9.9–32.9 %. Metabolic syndrome is more often observed in patients with schizoaffective disorder than in patients with schizophrenia; however, explanatory factors of this association deserve further research. Patients, receiving atypical neuroleptics, must undergo regular endocrinological examination and psychiatrists must draw attention to the endocrinological component of the patient’s health. Diabetologists and psychiatrists must work together to monitor patients treated with atypical antipsychotics, with the aim of identifying their impaired glucose tolerance and diabetes management.

References

Sinajko VM, Korovina LD, Zemljanicyna OV. Arhiv Psyhiatrii’ 2012; 18(3):13-17.

Sinajko VM, Zemljanicyna OV. Ukr Visn Psyhonevrologii’ 2010; 18(64):149-150.

Koller EA, Doraiswamy PM. Pharmacotherapy 2002; 22(7):841-852.

Kato M, Gonzalez-Bianco M, Sotelo J, et al. American Psychiatric Association Annual Meeting, San Francisco, 2003:211-213.

Davis JM, Chen N, Glick ID. Arch Gen Psychiatry 2003; 60:553-564.

Marinis TD, Saleem PT, Glue P, et al. Pharmacopsychiatry 2007; 40(6): 257-263.

Nasrallah HA. Molecular Psychiatry 2007.

Woodward ND, Purdon SE, Meltzer HY, Zald DH. Schizophr Res 2007; 89(1-3):211-224.

Kut’ko II, Panchenko OA, Rachkauskas GS, Linev AN. Novosti Mediciny i Farmacii 201; 316:467.

Elkis H. Psychiatr Clin North Am 2007; 30(3):511-533.

Stroup T, Lieberman J, McEvoy J. Am J Psychiatry 2006; 163:611-622.

Sanger T, Lieberman J, Tohen M, et al. Am J Psychiatry 1999; 156:79-87.

Jayaram M, Hosalli P, Stroup S. Cochrane Database Syst Rev 2006; 2:CD005237.

Leucht S, Komossa K, Rummel-Kluge C. Am J Psychiatry 2009; 166:152-163.

Mosolov SN. Biologicheskie metody terapii psihicheskih rasstrojstv (dokazatel’naja medicina —klinicheskoj praktike), Moskva, 2012: 1080 p.

Allison DB, Fontaine KR, Heo M, et al. J Clin Psychiatry 1999; 60:215-220.

Cooperberg AA, Edlow S. J Canad Med Assoc 1956; 75:746-749.

Mosolov SN, Kabanov SO. Social’naja i Klinich Psihiatrija 2003; 13(2):162.

Mosolov SN, et al. Social’naja i Klinich Psihiatrija 2008; 3:75.

Denisov EM. Metabolicheskij sindrom u bol’nyh shizofreniej: rol’ antipsihotikov. Soobshhenie 1. Zhurn Psihiatrii i Med Psihologii 2010; 1-2(24-25):151-160.

Shabanov PD, Sapronov NS. Psihonejrojendokrinologija, Sankt-Peterburg, 2010: 984 p.

Cohen D. J Mind Behav, 1994; 15:139-156.

Shjule G. Rukovodstvo k dushevnym boleznjam, Har’kov, 1988: 17-20; 98-100.

Polishhuk IA. Trudy Gosudarstvennogo nauchnoissledovatel’skogo psihonevrologicheskogo instituta im. VM. Behtereva, Leningrad, 1963; 29:157-169.

Orlovskaja DD. Aktual’nye problemy nevropatologii i psihiatrii, Moskva, 1974:212-222.

Belkin A.I. Klinicheskie osobennosti shizofrenii u bol’nyh s izmenennoj funkciej shhitovidnoj zhelezy, Moskva, 1960: 313 p.

Zhislin SG. Voprosy kliniki, patogeneza, lechenija shizofrenii, Moskva, 1958:172-188.

Skanavi EE. Problemy psihonevrologii detskogo vozrasta, Moskva, 1964:17-28.

Delay J, Deniker P, Harl JM, et al. Ann MédicoPsychologiques 1952; 110:112–117.

Avruckij GJa, Neduva AA. Lechenie psihicheskih bol’nyh, Moskva, 1988: 5 p.

ADA/APA/AACE/NAASO. Diabetes Care 2004; 27:596-601.

Mosolov SN. Osnovy psihofarmakoterapii, Moskva,1996: 283 p.

Belkin AI, Lakusta VN. Biologicheskaja terapija psihicheskih zabolevanij, Kishinev, 1983: 216 p.

Bartoli F, Crocamo C, Caslini M, et al. J Psychiatric Res 2015; 66–67:127-134.

Madhusoodanan S, Parida S, Jimenez C. Hum Psychopharmacol Clin Exp 2010; 25:281-297.

Green JK, et al. General Hospital Psychiatry 2000; 22:224-235.

Reiser LW, Reiser MF. Comprehensive Textbook of Psychiatry, New York, 1984:1024-1035.

Avedisova AS, Jastrebov DV, Borodin VI, Dashkina GK. Psihiatrija i psihofarmakoterapija. Zhurnal im. P.B. Gannushkina 2009; 11(2):6-13.

Thornnard–Neumann E. Am J Psychiatry 1986; 124:978-982.

Gorobec LH. Sovremennye problemy psihiatricheskoj jendokrinologii, Moskva, 2004:22-45.

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Endocr Pract 2015:1-28.

Gorobec LN, Bulanov VS, Litvinov AV, Vasilenko LM. Prakticheskie rekomendacii po diagnostike, korrekcii i profilaktike nejrojendokrinnyh disfunkcij u psihicheski bol’nyh v processe nejrolepticheskoj terapii, Moskva, 2010: 32 p.

Gorobec LN, Bulanov VS, Vasilenko LM. Zhurn nevrologii i psihiatrii im. S. S. Korsakova 2012; 112(9):90-96.

Gorobec LN. Teoreticheskie i prakticheskie aspekty psihonejrojendokrinologii 2012:11-39.

Sinajko VM, Korovina LD, Zemljanicyna OV. Tavrich Zhurn Psihiatrii 2011; 15(2):44-45.

Newcomer JW. J Clin Psychiatry 2007; 68.

Henderson DC, Cagliero E, Gray C. Am J Psychiatry 2000; 157:975-981.

Morozov PV. Psihiatrija i psihofarmakoterapija. Zhurnal im. PB. Gannushkina 2010; 5(12):28-29.

Lambert T, Chapmen LH. MJA 2004; 181(10):544-548.

Hennekens C Hennekens A, Hollar D. Am Heart J 2005; 150: 1115-1121.

Colton C, Manderscheid R. Prev Chronic Dis 2006; 3(2): A42.

Gorobec LN. Nejrojendokrinnye disfunkcii i nejrolepticheskaja terapija, Moskva, 2007: 312 p.

Downloads

Published

2021-08-17

How to Cite

Pidkorytov, V. S., Syerikova, O. I., Serikova, O. S., Baybarak, N. A., Ukrayinskyy, S. A., & Skrynnik, O. V. (2021). THE PROBLEM OF NEUROENDOCRINE DYSFUNCTIONS IN PATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER (literature review). Problems of Endocrine Pathology, 57(3), 100-112. https://doi.org/10.21856/j-PEP.2016.3.11

Most read articles by the same author(s)